Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
388
datasets available to search
ShareScore release 0.9.0
Dataset results
388 results for “immune checkpoint inhibitors”
Impact of PD-L1 overexpression on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model.
GEO Series GSE292013. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Colitis associated with immune checkpoint inhibitors [tissue_nuclei]
GEO Series GSE206300. Homo sapiens. 34 samples. Type: Expression profiling by high throughput sequencing.
ECP as a treatment for immune checkpoint inhibitor-induced colitis [array]
GEO Series GSE207823. Mus musculus. 10 samples. Type: Expression profiling by array.
Colitis associated with immune checkpoint inhibitors
GEO Series GSE206301. Homo sapiens. 152 samples. Type: Expression profiling by high throughput sequencing.
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
GEO Series GSE164444. Homo sapiens. 37 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma
GEO Series GSE184524. Mus musculus. 5 samples. Type: Expression profiling by array.
Colitis associated with immune checkpoint inhibitors [tissue_cells]
GEO Series GSE206299. Homo sapiens. 95 samples. Type: Expression profiling by high throughput sequencing.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
GEO Series GSE222934. Homo sapiens. 76 samples. Type: Expression profiling by high throughput sequencing; Genome variation profiling by high throughput sequencing; Methylation profiling by array.
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma [ChIP-seq]
GEO Series GSE164443. Homo sapiens. 20 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes
GEO Series GSE208644. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy (NGS)
GEO Series GSE222932. Homo sapiens. 51 samples. Type: Expression profiling by high throughput sequencing; Genome variation profiling by high throughput sequencing.
Genomic and transcriptomic analysis of Japanese melanoma reveals candidate biomarkers for immune checkpoint inhibitor responders.
GEO Series GSE282471. Homo sapiens. 111 samples. Type: Expression profiling by high throughput sequencing.
Using plasma cell-free mRNA to profile immune response and myocardial damage in immune checkpoint inhibitor-induced myocarditis
GEO Series GSE296680. Homo sapiens. 26 samples. Type: Expression profiling by high throughput sequencing.
Colitis associated with immune checkpoint inhibitors [blood_cells]
GEO Series GSE206298. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing.
raw data related to project "Circulating biomarkers as predictors of gender-specific response to Immune Checkpoint Inhibitors in melanoma and non-small-cell lung cancer patients"
<p><strong>Sex-related differences in serum biomarker levels predict the activity and efficacy of Immune Checkpoint Inhibitors in advanced melanoma and Non-Small Cell Lung Cancer patients.</strong></p> <p><strong>Abstract </strong></p> <p><strong>Background:</strong> Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival in patients with advanced malignant melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity and efficacy, and their sex interaction, could improve treatment personalization. </p> <p><strong>Methods: </strong>In this prospective study, we enrolled immunotherapy-naïve patients affected by advanced MM and NSCLC treated with ICIs. The primary endpoint was to dissect the potential sex correlations between serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, MCP-1, TNF-ɑ, IP-10, VEGF, sPD-L1) and the overall response rate (ORR). Secondly, we analyzed biomarker changes during treatment related to ORR, disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Blood samples, collected at baseline and during treatment until disease progression (PD) or up to 2 years, were analyzed using Luminex xMAP or ELLA based technology. </p> <p>Three Luminex xMAP assays and two ELLA microfluidic cartridges were used to screen 28 immune-related biomarkers in 38 paired serum and citrate-theophylline-adenosine-dipyridamole (CTAD) plasma samples collected from 10 advanced melanoma or non-small cell lung cancer (NSCLC) patients at different time points during immunotherapy.</p> <p><strong>Results</strong>: Serum samples from 161 patients (98 males/63 females; 92 MM/69 NSCLC) were analyzed for treatment response. At baseline, IL-6 was significantly lower in females (F) <em>versus</em> males (M); lower levels of IL-4 in F and of IL-6 in both sexes significantly correlated with a better ORR, while higher IL-4 and TNF-ɑ values were predictive of a lower probability of ORR in F <em>versus</em> M. One hundred and sixty-five patients were evaluable for survival analysis: at multiple Cox regression, an increased risk of PD was observed in F with higher baseline values of IL-4, sPD-L1 and IL-10, while higher IL-6 was a negative predictor in males. In males, higher levels of GM-CSF predict a longer survival, whereas higher IL-1β predicts a shorter survival. Regardless of sex, high baseline IL-8 values were associated with an increased risk of both PD and death, and high IL-6 levels only with shorter OS. </p> <p>Twenty-three of 28 biomarkers were detected both in serum and plasma by at least one of the assays, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, IFN-γ, TNF-α, VEGF, IP-10, MCP-1, eotaxin, fractalkine, G-CSF, IFN-α, IL-1RA, IL-13, IL-17A, MIP-1β and sPD-L1. Conversely, FGF-2 and IL-1α were not detected in both matrices; GRO-α factor and EGF were detected only in serum and MIP-1α only in plasma. sPD-L1, MCP-1, IFN-γ, IL-8, MIP-1β and VEGF were, respectively, 1.15-, 1.44-, 1.83-, 2.43-, 2.82-, 6.72-fold higher in serum, whereas IL-10, IL-4, IL-2 and IL-5 were 1.05-, 1.19-, 1.92- and 2.17-fold higher, respectively, in plasma. IP-10 levels were higher in plasma but, as well as for VEGF, the bias serum versus plasma varied depending on the assay used (IP-10: −5.7% to −145%; VEGF: 115% to 165%). No significant differences were found for the remaining nine analyzed cytokines.</p> <p><strong>Conclusions</strong></p> <p>Serum IL-1β, IL-4, IL-6, IL-10, GM-CSF, TNFɑ, and sPDL1 had a significant independent sex-related predictive impact on ORR, PFS and OS in melanoma and NSCLC patients treated with ICIs. These results will potentially pave the way for new ICI combinations, designed according to baseline and early changes of these cytokines and stratified by sex. </p> <p>The cytokine and sPD-L1 levels may differ between serum and plasma samples collected from cancer patients treated with immunotherapy, and the results obtained can be influenced by the different characteristics of the tested assays.</p>
Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
ClinicalTrials.gov study NCT04473703. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS
ClinicalTrials.gov study NCT06902038. IPD Sharing: NO. Countries: 0. Publications: 0.
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of E
ClinicalTrials.gov study NCT07376499. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
ClinicalTrials.gov study NCT06279403. IPD Sharing: NO. Countries: 0. Publications: 0.
Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT07028008. IPD Sharing: NO. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.